No.2
Alimera Sciences (NASDAQ:ALIM) announces that ILUVIEN has fulfilled all requirements for registration for approval. Alimera's partner, MEAgate International, Dubai, will be responsible for obtaining pricing and launching ILUVIEN in Kuwait.
ILUVIEN is a sustained release intravitreal implant indicated to treat diabetic macular edema in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure.
返信
投資の参考になりましたか？
